Spotting head and neck cancer symptoms in community pharmacies in Dundee and sharing information with GP practices

Not Applicable

Completed

• Conditions: Identification of possible head and neck cancer symptoms in community pharmacy; Cancer

• Registration Number: ISRCTN16102051
• Lead Sponsor: HS Tayside

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-04-26
• Study Completion: 2024-02-28
• Last Update Posted: 25 March 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Any adult (age 18 years+), registered with a GP in Dundee City, who presents to one of the participating pharmacies with relevant symptoms as outlined in the protocol
2. Participating community pharmacists
3. GPs/clinicians who review patient participant(s)

Exclusion Criteria

1. People without symptoms meeting study criteria
2. People not registered with a GP in Dundee City
2. Non-consenting individuals
3. Any person under the age of 18 years
4. Any person unable to participate in a consultation conducted in the English language

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Acceptability of the pathway is measured by: <br>1.1. Patient/public uptake at baseline <br>1.2. Patient/public feedback via questionnaire at 0-4 weeks and/or interview at 4 weeks <br>1.3. Pharmacy team feedback at week 24 (end of the recruitment period)<br>1.4. GP/practice staff feedback via questionnaire at week 4 and/or interview at week 24

Secondary Outcome Measures

Name	Time	Method
1. Can a community pharmacy pathway identify people suspected of having head and neck cancer? Measured by number of completed community pharmacy head and neck cancer assessment tools at baseline. <br>2. To assess whether community pharmacists can accurately and reproducibly utilise the symptom assessment tool to enable confidence in their use by referral recipients. Measured by GP/practice staff feedback via questionnaire at week 4 and/or interview at week 24. <br>3. Do people advised by community pharmacy teams to seek further review, attend for further assessment of their symptoms? Measured by obtaining information on participant follow up with general practices at week 4. <br>4. Are people identified by this pathway referred onwards by primary care for further investigations? Measured via participant follow-up via national datasets using CHI number at week 24.<br>